According to BeiGene's announcement, total global revenue for the third quarter of 2026 was US$1,890 million, up 34% year on year; GAAP net profit was US$385 million, up 208 percent year on year. The core product, Baiyuze®, had global revenue of US$1.4 billion in the third quarter, up 34% year over year. The company raised its total revenue guidance for the full year 2026 to US$6.9 billion to US$7 billion, and GAAP operating profit guidance to US$1.2 billion to US$1.3 billion. In addition, clinical and regulatory progress has been made in various products and ongoing research pipelines.

According to BeiGene's announcement, total global revenue for the third quarter of 2026 was US$1,890 million, up 34% year on year; GAAP net profit was US$385 million, up 208 percent year on year. The core product, Baiyuze®, had global revenue of US$1.4 billion in the third quarter, up 34% year over year. The company raised its total revenue guidance for the full year 2026 to US$6.9 billion to US$7 billion, and GAAP operating profit guidance to US$1.2 billion to US$1.3 billion. In addition, clinical and regulatory progress has been made in various products and ongoing research pipelines.